Pregnancy and heart disease pulmonary hypertension: Difference between revisions
No edit summary |
No edit summary |
||
| Line 58: | Line 58: | ||
'''2.'''The use of single-barrier contraception alone in women with CHD-PAH is not recommended owing to the frequency of failure. (Level of Evidence: C) | '''2.'''The use of single-barrier contraception alone in women with CHD-PAH is not recommended owing to the frequency of failure. (Level of Evidence: C) | ||
'''3.'''Estrogen-containing contraceptives should be avoided. (Level of Evidence: C) | '''3.'''Estrogen-containing contraceptives should be avoided. (Level of Evidence: C)}} | ||
Revision as of 17:17, 8 October 2011
|
Cardiac disease in pregnancy Microchapters |
|
Diagnosis |
|---|
|
Catheterization: |
|
Treatment |
|
Special Scenarios:
|
|
Pregnancy and heart disease pulmonary hypertension On the Web |
|
American Roentgen Ray Society Images of Pregnancy and heart disease pulmonary hypertension |
|
Pregnancy and heart disease pulmonary hypertension in the news |
|
Directions to Hospitals Treating Cardiac disease in pregnancy |
|
Risk calculators and risk factors for Pregnancy and heart disease pulmonary hypertension |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Anjan K. Chakrabarti, M.D. [2]
Overview
This section will review pulmonary hypertension and its association with pregnancy. For a more broad discussion, please see pulmonary hypertension.
Pulmonary hypertension, defined as mean pulmonary artery pressure of greater than 25 mmHg at rest or 30 mmHg with exercise, carries a higher mortality when it is associated with pregnancy. It carries a significant risk to mother and child during pregnancy; as a result, mothers require careful monitoring.[1]
Classification
Physiologic Considerations in Pregnancy
As reviewed in |Physiologic Changes Associated with Pregnancy, maternal blood volume increases throughout pregnancy until between 28 and 34 weeks of gestation, and circulating blood volume is increased to between 30% and 50% above the non-pregnant state. Red blood cell mass increases to approximately 25% above the non-pregnant state. Cardiac output increases through various mechanisms, and hyper coagulability is noted in the postpartum state due to relative resistance to activated protein C, reduced serum levels of protein S and increased levels of factors I, II V, VII, VIII, X and XII.[2]
All of these changes can be particularly deleterious in patients with PAH. It can be very harmful if a thrombus forms or embolises to an already compromised pulmonary circulation. Such hematological changes present a significant risk, and mortality fall between 30% and 50% for pregnant women with idiopathic PAH.[3]
Specific Issues with PAH and Pregnancy
- Longterm elevation of pulmonary vascular resistance may cause right ventricular hypertrophy or dilatation, tricuspid regurgitation or arrhythmias, leading to intolerance of the increased heart rate and circulating blood volume of pregnancy.
- Cardiac output may already be reduced by pulmonary hypertension, and the heart may not be able to increase cardiac output in proportion to the reduced systemic vascular resistance that occurs during pregnancy.
- Normal adaptive changes in the lungs to accommodate the increased pulmonary blood flow may be prevented by fixed vascular remodeling.
- Hypercoagulability may increase the tendency for thrombus formation, which may be poorly tolerated (as above).
- Patients are at risk for sudden death from pulmonary hypertensive crises, malignant arrhythmias or pulmonary thromboembolism.
- Patients can develop stroke from intracardiac shunting in pre-existing Eisenmenger’s syndrome or if there is a persistent patent foramen ovale[4]
Outcomes and Recommendations
In a review of PAH and pregnancy outcomes between 1978 and 1996, Weiss and colleagues[3] found a maternal mortality rate of 30% in idiopathic PAH, 36% in Eisenmenger’s syndrome and 56% in pulmonary hypertension secondary to a variety of other conditions including liver disease, connective tissue disease, chronic thromboembolic events and ingestion of slimming agents. Of note, the highest mortality was in the first month after delivery.
As a result, many authors recommend pregnancy should be avoided in the setting of maternal PAH.[5]. See guidelines below.
Pulmonary hypertension/Eisenmenger physiology. In: ACC/AHA 2008 guidelines for the management of adults with congenital heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
| “ |
Recommendations for ReproductionClass I1.Women with severe CHD-PAH, especially those with Eisenmenger physiology, and their partners should be counseled about the absolute avoidance of pregnancy in view of the high risk of maternal death, and they should be educated regarding safe and appropriate methods of contraception. (Level of Evidence: B) 2.Women with CHD-PAH who become pregnant should:
Class IIb1.Pregnancy termination in the last 2 trimesters of pregnancy poses a high risk to the mother. It may be reasonable, however, after the risks of termination are balanced against the risks of continuation of the pregnancy. (Level of Evidence: C) Class III1.Pregnancy in women with CHD-PAH, especially those with Eisenmenger physiology, is not recommended and should be absolutely avoided in view of the high risk of maternal mortality. (Level of Evidence: B) 2.The use of single-barrier contraception alone in women with CHD-PAH is not recommended owing to the frequency of failure. (Level of Evidence: C) 3.Estrogen-containing contraceptives should be avoided. (Level of Evidence: C) |
” |
References
- ↑ Madden BP (2009). "Pulmonary hypertension and pregnancy". Int J Obstet Anesth. 18 (2): 156–64. doi:10.1016/j.ijoa.2008.10.006. PMID 19223169.
- ↑ PECHET L, ALEXANDER B (1961). "Increased clotting factors in pregnacy". N Engl J Med. 265: 1093–7. doi:10.1056/NEJM196111302652205. PMID 14484810.
- ↑ 3.0 3.1 Weiss BM, Zemp L, Seifert B, Hess OM (1998). "Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996". J Am Coll Cardiol. 31 (7): 1650–7. PMID 9626847.
- ↑ Jaigobin C, Silver FL (2000). "Stroke and pregnancy". Stroke. 31 (12): 2948–51. PMID 11108754.
- ↑ Weiss BM, Hess OM (2000). "Pulmonary vascular disease and pregnancy: current controversies, management strategies, and perspectives". Eur Heart J. 21 (2): 104–15. doi:10.1053/euhj.1999.1701. PMID 10637084.